- Post-Doctoral: Cancer Biology, University of California, San Francisco.
- PhD: Yale University School of Medicine.
- BA: University of California, Berkeley.
- Kim S. (2015) New and emerging factors in tumorigenesis: an overview. Cancer Manag Res. 7:225-39. PMID: 26251629
- Keenen MM and Kim S. (2016) Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells. Breast Cancer (Dove Med Press) 8:211-221. PMID: 27895513
- Byron SA, Min E, Thal TS, Tapia C, Hostetter G, Watanabe A, Azorsa D, Little TH and Kim S. (2012) Attenuation of NF-kappa B by the ING4 tumor suppressor in breast cancer. PLoS One 7(10):e46823.
- Tapia C, Zlobec I, Schneider S, Kilic E, Guth U, Bubendorf L and Kim S. (2011) Deletion of the ING4 tumor suppressor gene is prevalent in HER2-positive breast cancer. Human Pathology 42(7): 983-90.
- Kim S, Welm AL and Bishop JM. (2010). A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Res 70:5155-5162.
For a complete listing of Dr. Kim's publications, search PubMed.
Cancer, tumor suppressors, gene regulation
We investigate tumor suppressor (TS) genes in cancer and how TS deficiencies lead to tumor formation and progression. We have characterized Inhibitor of Growth 4 (ING4) TS in breast cancer, of which deficiency is correlated with metastatic and therapy-resistant tumors. We have defined ING4 as a transcriptional regulator that plays a critical role in tumor-immune modulation and hormone response. Ongoing studies include the molecular mechanism of ING4 and TSs in neuroblastoma and lung cancer.